One of the most fascinating and difficult tasks for researchers is to create floating tablets with the necessary buoyancy, lag time, and control over the drug's release behaviour at the target spot. The goal of the current study is to develop effervescent floating controlled release tablets containing famotidine and clarithromycin for the treatment of peptic ulcers caused by Helicobacter pylori (H. pylori). Five formulations (F1-F5) were created, three of which had bilayered tablets and the other four contained plain tablets. Sodium bicarbonate, HPMC K4M, and hydroxypropyl methylcellulose (HPMC) K100M were used as the swelling and floating agents, respectively, in the direct compression process used to create these tablets. To guarantee the quality of the produced tablets, qualitative tests including thickness, hardness, weight variation, friability, and content consistency were carried out. Every formulation had a floating lag time that varied between 14 and 20 seconds. The HPMC K100M-prepared effervescent floating tablets (F2 & F4) had a total floating duration of less than 7 hours, but the HPMC K4M-prepared tablets (F1, F3, & F5) had a total floating time of more than 12 hours. One possible explanation for this discrepancy in floating behaviour is that the two polymers' compaction and flow characteristics differ. When contrasted to formulations F1, F3, and F4 that use HPMC K4M as swelling and floating polymer, formulations F2 and F4 using HPMC K100M show relatively more prolonged drug release capabilities. This may be explained by HPMC K100M's improved compaction. The produced tablets exhibit diffusion kinetics that are non-Fickian. All things considered, these plain and floating controlled release effervescent bilayer tablets may improve famotidine and clarithromycin's therapeutic effects and compliance when used to treat H. pylori.